Literature DB >> 17434830

Trends in risk factors and etiology of 606 cases of infective endocarditis over 23 years (1984-2006) in slovakia.

V Hricak1, B Liska, J Kovackova, J Mikusova, V Fischer, J Kovacik, M Karvaj, R Jurco, A Ondrusova, E Kalavsky, P Marks, P Beno, V Krcmery.   

Abstract

The aim of this study was to assess trends in risk factors, etiology, outcome and treatment strategies for endocarditis over 23 years in Slovakia. A prospective survey of 606 cases of infective endocarditis (IE) was conducted from 1984-2006. Rheumatic fever as well as previous dental surgery showed decreasing trends within the last 23 years. Also embolic complications of IE declined along with increasing rates of surgically treated patients. No significant changes in etiology were detected apart from the fact that culture-negative endocarditis increased from 10.7% to 55.4% between 1998-2001. Surgically treated patients increased from 22.7% (1984-1990) to 50.1% (2002-2006) and mortality dramatically decreased from 26.7% (1984-1990) to 5.3% (2002-2006). Staphylococcus aureus and coagulase-negative staphylococci were the leading causes (22.4% - 48%) followed by viridans streptococci (12.2%-18.2%) were a relatively stable trend over 23 years of IE in Slovakia.

Entities:  

Mesh:

Year:  2007        PMID: 17434830     DOI: 10.1179/joc.2007.19.2.198

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

Review 1.  The causative agents in infective endocarditis: a systematic review comprising 33,214 cases.

Authors:  Christiana T Vogkou; Nikolaos I Vlachogiannis; Leonidas Palaiodimos; Antonis A Kousoulis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-11       Impact factor: 3.267

Review 2.  Infective endocarditis epidemiology over five decades: a systematic review.

Authors:  Leandro Slipczuk; J Nicolas Codolosa; Carlos D Davila; Abel Romero-Corral; Jeong Yun; Gregg S Pressman; Vincent M Figueredo
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.